Viral vectors

Our capabilities include generation, production, purification and analysis of viral vector-based products manufactured on mammalian cell lines.

Viral vectors are very attractive for product development, as they hold the promise of providing a platform to manufacture diverse products. For instance, a malaria vaccine, AIDS vaccine, or tuberculosis vaccine could be developed by inserting immunostimulatory genes from the Plasmodium falciparum parasite, the human immunodeficiency virus (HIV) or Mycobacterium tuberculosis bacteria, respectively, into a vector. However, for some vector systems, anti-vector immune responses must be taken into consideration; a viral vector product may elicit not only the intended immune response against the inserted target protein, but also an inadvertent response against the vector itself. This anti-vector immune response limits a repeat administration of the same viral vector product. For this reason, many viral vector products currently under development involve a combination of different viral vectors as part of a prime-boost vaccination strategy. For example, an adenoviral vector is used for priming, followed by the MVA used for a booster. These prime-boost regimens ensure long-term immunity and protection.

Viral vector track record

We have extensive experience in manufacturing a wide range of viral vectors including AAV, adenoviruses, lentiviruses, measles virus and VSV. We are proud to have manufactured viral vector-based gene therapy products as well as vaccine products for phase-I and phase-II clinical studies in both the EU and US markets. Our experience in the field, anchored in production, purification, and testing protocols, has resulted in a successful track record in delivering viral vector-based products. For example, in a collaboration with Prof. Frank Staal (Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Netherlands), we have delivered several lentiviral vector-based products for a candidate treatment for children suffering from Severed Combined Immuno-Deficiency (SCID). In addition, in collaboration with Prof. Andrew Baker (Centre for Cardiovascular Science, University of Edinburgh), we have successfully developed and manufactured novel adenoviral vectors for development of therapies against cardiovascular diseases. And together with IAVI, we are currently developing a VSV vector-based vaccine against Lassa fever.

Learn more about process development for viral vectors in our complete guide:

Visit guide to viral vector production

I have greatly enjoyed working with Batavia Biosciences on the clinical manufacturing of lentiviral vectors. In particular, I appreciated their adherence to timelines and budget, their pro-active communication and problem-solving capabilities.

Prof. Frank StaalLeiden University Medical Center

The team at Batavia was excellent in both their communication, know-how and operational performance with regards to the development and manufacturing of adenoviral vectors.

Prof. Andrew BakerUniversity of Edinburgh

We’re proud to call Batavia Biosciences an IAVI collaborator since 2012 as both organizations share a common goal to develop vaccines that are affordable and accessible to address infectious disease globally. Batavia has been instrumental in the development of cell lines, process, and analytics to support IAVI’s manufacturing and development of HIV vaccine viral vectors, in particular for the vesicular stomatitis virus (VSV) platform for clinical testing. Building on this experience, IAVI and Batavia are extending this innovative collaboration to include use of the VSV platform for the development of vaccines for other emerging infectious diseases that disproportionately affect people living in poverty.

Mark Feinberg, M.D., Ph.DIAVI President and CEO

Viral vectors technologies


SCOUT® technology

The SCOUT® technology provides for an effective tool for “Design-of-Experiments” (DoE) approaches. It uses a miniaturized production and purification platform to rapidly develop multivariate processes.

Learn more

SIDUS® technology

The SIDUS® platform combines our biological materials (cell lines and vector systems) with our in-depth experience and complete protocol systems for manufacturing viral vector-based vaccine, oncolytic and gene therapy products.

Learn more

Process development

We develop scalable, robust and GMP-compliant manufacturing processes for viral vectors.

Upstream process development

We deliver scalable and robust GMP-compliant manufacturing processes for viral vectors. At Batavia Biosciences, we operate a range of different manufacturing scales and utilize diverse cell culture equipment for both adherent growth and growth in suspension.

Learn more

Downstream process development

We deliver scalable and robust GMP-compliant processes for the purification of viral vectors. The different upstream process formats and scales are matched with appropriately scaled downstream equipment for clarification, concentration, chromatography and filtration.

Learn more

Analytical development

We perform and develop all the required product-specific release and stability-determining assays for your viral vector product.

Learn more

In silico cost modeling

When you are developing a viral vector product, such as vectored vaccines, gene therapies or oncolytic viruses, a robust, cost-effective, and high yielding manufacturing process will support your product’s financial viability.

Learn more

Related resources

Driving down COGs of viral vector-based biopharmaceuticals

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
How do you keep cost of goods (COGs) for viral vector-based medicines within reason to develop a product that is both affordable and financially viable?  In this 3-part series we…
adenoviral vector product from bench to clinic

Taking your adenoviral vector product from R&D to the clinic

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenoviruses have been shown to be very effective vehicles for delivering genetic material to cells and are therefore in demand to develop gene therapies and vaccine products. The road from…
Adenovirus vectors gene therapy and vaccine development

Adenovirus vectors: cutting edge delivery vehicles for gene therapy and vaccine development

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenovirus (Ad) vectors are used to develop gene therapy products and vaccines. Decades of research stand behind these vectors which have gone through several iterations and improvements to make them…
Past and current challenges of adenoviral vector platforms

Adenoviral vector platform: past and current challenges

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenoviruses have been explored for gene therapy purposes for many decades. They are DNA viruses, with a double-stranded DNA genome of around 26-45 kilobases. Adenoviruses have been isolated from a…
Process development
Preclinical manufacturing
Knowledge center

Talk to our experts

Alfred Luitjens - Bioprocess expert
Alfred Luitjens

Global Technical Sales Director
+31 (0) 88 9950600

Send us a message